Compare Altria Group Inc (MO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs TransMedics Group Inc — how do they compare? Altria Group Inc trades at $64.49 (market cap $108.58B), while TransMedics Group Inc trades at $87.13 (market cap $3.10B). The key difference: Altria Group Inc is far larger — about 35× TransMedics Group Inc's market cap, and Altria Group Inc pays a 6.52% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MO | TMDX | |
|---|---|---|
Market Cap | $108.58B | $3.10B |
Sector | Consumer Staples | Technology |
52-Week High | $74.92 | $150.42 |
52-Week Low | $54.72 | $61.99 |
Enterprise Value | $130.79B | $3.49B |
Dividend Yield | 6.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $64.47, down 1.63% today, with a bearish technical signal despite oversold RSI readings near 18-27. The company maintains strong profitability with 39% net income margins and a 6.3% dividend yield, though recent earnings show mixed results with two misses in the last four quarters. Cash flow improved significantly in 2025 with $1.33B net inflow, while debt remains elevated at $23.4B long-term.
Investment outlook balances high yield and dividend consistency against cigarette volume declines and regulatory risks. Analyst consensus remains bullish with a $67 price target, but ongoing litigation investigations and smoke-free transition execution pose significant challenges. The stock offers value at 13.7x P/E but requires careful monitoring of diversification efforts.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
